NCT07893457
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Total Esophageal Acid Exposure Time During 96-Hour Wireless pH Monitoring
Timeframe: During the 96-hour wireless pH monitoring period, completed within 40 days after enrollment.
Secondary (11)
Number of Days With Abnormal Esophageal Acid Exposure During 96-Hour Wireless pH Monitoring
Composite DeMeester Score During Wireless pH Monitoring
Esophagogastric Junction Distensibility Index Measured by Functional Lumen Imaging Probe
Maximum Esophagogastric Junction Diameter Measured by Functional Lumen Imaging Probe
Resting Lower Esophageal Sphincter Pressure Measured by High-Resolution Manometry
Show 6 moreShow less
Integrated Relaxation Pressure Measured by High-Resolution Manometry
Mean Proximal Intragastric Pressure Before Seated Swallows
Mean Proximal Intragastric Pressure During Swallow-Induced Esophagogastric Junction Opening
Mean Proximal Intragastric Pressure Immediately After Swallow-Induced Esophagogastric Junction Closure
Change From Baseline to Day 7 in Gastroesophageal Reflux Disease Health-Related Quality of Life Total Score
Change From Baseline to Day 7 in Brief Esophageal Dysphagia Questionnaire Total Score
Arms and interventions
PlaceboPlacebo comparator
Once subcutaneous injection
TirzepatideActive comparator
Tirzepatide 7.5 mg subcutaneous injection
Drugs: Placebo, Tirzepatide
Sites
1 site in 1 country
- Mayo ClinicRochester, Minnesota, United States